Fig. 6
Changes in serum chemokine levels as early biomarkers of response to anti-HER2 antibody-based neoadjuvant treatment in HER2-positive primary breast cancer. CCL5, CXCL9 and CXCL10 levels were analysed by ELISA in longitudinal serum samples from HER2-positive breast cancer patients undergoing anti-HER2 antibody-based neoadjuvant treatment. Samples were obtained prior to treatment initiation (baseline, n = 79), after 3 chemotherapy cycles (Post-chemo; n = 32). A Scheme indicating the number of baseline and paired longitudinal serum samples for each time point; the percentage of pathological complete response (pCR) in each patient group; and patients with TILs and TI-NK cell data available. B CCL5, CXCL9 and CXCL10 levels in paired baseline (pre) and post-chemotherapy (post) serum samples in patients stratified as good (G4 and G5) or poor (G1-3) responders to anti-HER2 antibody-based neoadjuvant treatment by Miller and Payne criteria. C TIL score and TI-NK cell numbers in diagnostic biopsies of the analysed cohort, stratified by response to treatment according to Miller and Payne. Statistical significance by Mann Whitney U test is indicated. D Spearman correlation coefficient between baseline TIL score and TI-NK cell numbers and post-chemotherapy CCL5; CXCL9 and CXCL10. Significant correlations are indicated